The price of Journey Medical Corp (NASDAQ: DERM) closed at $3.69 in the last session, up 26.37% from day before closing price of $2.92. In other words, the price has increased by $+0.7700 from its previous closing price. On the day, 638091 shares were traded.
Ratios:
We take a closer look at DERM’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.00. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.35. In the meantime, Its Debt-to-Equity ratio is 0.87 whereas as Long-Term Debt/Eq ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on December 07, 2021, initiated with a Buy rating and assigned the stock a target price of $14.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 22 ’24 when Smith Justin Adam bought 30,000 shares for $3.47 per share. The transaction valued at 104,100 led to the insider holds 134,717 shares of the business.
ROSENWALD LINDSAY A MD bought 20,000 shares of DERM for $68,000 on Mar 22 ’24. The Director now owns 134,245 shares after completing the transaction at $3.40 per share. On Mar 22 ’24, another insider, Maraoui Claude, who serves as the President & CEO of the company, bought 10,000 shares for $3.48 each. As a result, the insider paid 34,790 and bolstered with 2,163,430 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DERM now has a Market Capitalization of 71.11M and an Enterprise Value of 46.49M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.90 while its Price-to-Book (P/B) ratio in mrq is 3.50. Its current Enterprise Value per Revenue stands at 0.58 whereas that against EBITDA is -8.17.
Stock Price History:
Over the past 52 weeks, DERM has reached a high of $8.11, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is 4.2310, while the 200-Day Moving Average is calculated to be 3.5421.
Shares Statistics:
According to the various share statistics, DERM traded on average about 206.76K shares per day over the past 3-months and 241.1k shares per day over the past 10 days. A total of 13.32M shares are outstanding, with a floating share count of 6.43M. Insiders hold about 66.71% of the company’s shares, while institutions hold 6.94% stake in the company. Shares short for DERM as of Feb 29, 2024 were 64.39k with a Short Ratio of 0.31, compared to 70.7k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.35% and a Short% of Float of 0.72%.
Earnings Estimates
The company has 3 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.26, while EPS last year was -$0.57. The consensus estimate for the next quarter is -$0.12, with high estimates of $0.03 and low estimates of -$0.23.
Analysts are recommending an EPS of between $0 and -$0.83 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is $0.03, with 3 analysts recommending between $0.5 and -$0.6.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $14.53M. It ranges from a high estimate of $15.39M to a low estimate of $13.29M. As of the current estimate, Journey Medical Corp’s year-ago sales were $12.21M, an estimated increase of 19.00% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $15.51M, an increase of 4.70% less than the figure of $19.00% in the same quarter last year. There is a high estimate of $17.49M for the next quarter, whereas the lowest estimate is $14.4M.
A total of 3 analysts have provided revenue estimates for DERM’s current fiscal year. The highest revenue estimate was $66.73M, while the lowest revenue estimate was $57.98M, resulting in an average revenue estimate of $60.92M. In the same quarter a year ago, actual revenue was $79.18M, down -23.10% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $94.44M in the next fiscal year. The high estimate is $119.25M and the low estimate is $64.03M. The average revenue growth estimate for next year is up 55.00% from the average revenue estimate for this year.
